Market Overview

Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019


Company Placing Priority on Investor Engagement with New Website,
Email Updates

a clinical-stage gene therapy company developing a new approach to
treating cancer based upon a novel proprietary technology platform,
announced today that it will be increasing its investor relations
efforts in 2019, spearheaded by the launch of an innovative corporate
website with more robust investor resources, including the company's
presentations, stock charts and integrated quotes, SEC filings, news,
media coverage, and tailored email newsletters, among other advanced
communication tools. As part of today's announcement, investors already
have the ability to receive all news regarding Genprex straight to their
inbox by signing up for the company's communication list at

In addition to the new investor relations initiatives, Genprex will also
be retaining the services of expert media relations and public relations
firms with the express purpose of increasing the quantity and improving
the quality of investor communications. Genprex also plans to use modern
tools like social media for greater distribution of news and company
announcements. According to Genprex CEO Rodney Varner, engagement and
outreach with investors will be among the company's top priorities in

"We're extremely excited about the added emphasis on investor
communications and relations in the new year," said Varner. "We believe
that the drug candidates that we are working to develop every day at
Genprex are groundbreaking and we recognize the importance in keeping
investors abreast of our team's initiatives and successes. With the new
website and email newsletters we will be launching, we intend to provide
to current and potential investors unprecedented insight into what is
happening at Genprex as we continue to work at the forefront of the new
age of immunogene therapy cancer treatments."

The company's new investor relations initiatives come on the heels of
months of promising developments at Genprex.

In October, Jan Stephens, RN, joined the company's Cambridge,
Massachusetts office as Genprex's new Vice President of Clinical
Operations, bringing with her nearly 20 years of comprehensive clinical
operations experience in the biopharma industry and a specialization in
early-to-late stage oncology companies. Stephens joined the company to
help support the various clinical development programs for Genprex's
proprietary immunogene therapy, Oncoprex™.

In addition to adding Stephens to its clinical leadership team, Genprex
also entered into a significant agreement with The University of Texas
MD Anderson Cancer Center to extend two option agreements between
Genprex and MD Anderson pertaining to the use of TUSC2, the active agent
in Oncoprex.

Forward-Looking Statements

Statements contained in this press release that are not statements of
historical facts are "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because these
statements are subject to risks and uncertainties, the actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effect of TUSC2 on cancer, the services we
expect to receive from media relations and public relations firms and
the effect of those services and statements about Genprex's business
plans. Risks that contribute to the uncertain nature of the
forward-looking statements include: the presence and level of TUSC2's
effect on cancer; the ability of media relations and public relations
firms to provide value to the company and the company's ability to
utilize those services; Genprex's ability to negotiate and execute final
technology license agreements under the extended options with MD
Anderson; and the nature and scope of protection ultimately provided
under any of the licensed patents and patent applications should such
technology license agreements be executed. These and other risks and
uncertainties are described more fully under the caption "Risk Factors"
and elsewhere in Genprex's filings and reports with the United States
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which they
were made. Genprex does not undertake any obligation to update these
statements to reflect any events that occur or facts that exist after
the date on which the statements were made.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new
approach to treating cancer based upon a novel proprietary technology
platform, including Genprex's initial product candidate, Oncoprex™
immunogene therapy for non-small cell lung cancer (NSCLC). Genprex's
platform technologies are designed to administer cancer fighting genes
by encapsulating them into nanoscale hollow spheres called nanovesicles,
which are then administered intravenously and taken up by tumor cells
where they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts cell
signaling pathways that cause replication and proliferation of cancer
cells, re-establishes pathways for apoptosis, or programmed cell death,
in cancer cells, and modulates the immune response against cancer cells.
Oncoprex has also been shown to block mechanisms that create drug
resistance. Visit the company's web site at
or follow Genprex on Twitter at
and Facebook at

View Comments and Join the Discussion!
Fastest news service for the smartest traders
$147 Free 14 day Trial